

Setting up the ICHOM /wAMD Community in Spain

Gonzaga Garay¹, Carolina Varela², Bernardo García³, Genaro Borrás⁴ & Carles Blanch⁴


¹OSI Araba, Vitoria-Gasteiz; ²Hospital 12 de Octubre, Madrid; ³Independent Senior Consultant and Researcher, Bilbao; ⁴Novartis Farmacéutica S.A., Barcelona, España.

Key Points

- Wet Age-related Macular Degeneration (wAMD) treatment is overwhelming the hospitals, with many patients going back and forth for their treatments with an overall burden of visits heavily increasing.
- Standardize the approach of wAMD treatment should help to deliver the best quality for the patients whilst helping the system to become sustainable.
- A network of hospitals working in a standardized manner must become the seed for transforming wAMD approach in Spain.

INTRODUCTION


- The age-related macular degeneration (wAMD) is a chronic disease that affects the elderly population, currently a demographic group fast growing. Therefore, wAMD has a negative impact in patients and caregivers quality of life and on healthcare system resources allocation. So, the burden of the disease and the need for efficiency in the allocation of limited resources make necessary to optimize the management of those patients.
- Furthermore, wAMD is a perfect condition to start implementing the value-based healthcare framework and, within this framework, the ICHOM data sets are the perfect tool to standardize the data recordings and guarantee external comparison. Patients suffering of wAMD need a life-long treatment periodically administered, exclusively at hospital settings. There are several drug therapies with different administration regimes available to treat these patients.
- Even though, the impact in quality of life and the costs of the treatments both the patient journey through the healthcare system and the medical decisions are defined with minimal participation of patients or taking into account the health outcomes derived from the care.



OBJECTIVE

- To improve the health outcomes of wAMD patients, creating a benchmark community of Hospitals in Spain. Therefore, the hospitals from the community will systematically measure and monitor the health outcomes in wAMD patients in real life conditions, thus during the routine healthcare.

METHOD



IMPACT

- This is one of the first experiences of measuring health outcomes in ophthalmology in Spain.
- This is a 3 years plan where we have engaged hospitals and other stakeholders in a common project to improve healthcare based on health outcomes that matter to patients and therefore will have an important social impact.
- It brings a big opportunity to engage all hospital stakeholders in a common project to transform health care based on medical results and social impact, and putting medical service users in the center.
- The plan is part of the Novartis strategy to help medical societies, caregivers, health policy makers and patients to transform the approach for delivering the best possible care to the wAMD